GlassScriptPhysician profile
Jason W Friday
NPI 1134352933
$18,283.48
in general payments reported to CMS, 2019-2025
38 companies · $3,382 in 2025
The $3,382 reported for 2025 was more than what 96% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $1,757 · 2021: $2,345 · 2022: $2,806 · 2023: $2,886 · 2024: $3,351 · 2025: $3,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,515 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,515.15 |
| Education | $102.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,206.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,597.43 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $1,449.89 | 2019-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,216.33 | 2020-2025 | Caplyta |
| Corium, LLC | $1,202.22 | 2021-2025 | Azstarys |
| Lundbeck LLC | $1,181.09 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,052.59 | 2019-2022 | |
| Axsome Therapeutics, INC. | $940.94 | 2022-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $887.94 | 2019-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $751.40 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $603.60 | 2019-2025 | Spravato |
| Allergan, INC. | $567.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $505.23 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $476.98 | 2021-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $466.13 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $441.13 | 2019-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $385.13 | 2019-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $310.94 | 2021-2023 | Belsomra |
| Bausch Health US, LLC | $289.77 | 2019-2025 | Aplenzin |
| Jazz Pharmaceuticals INC. | $260.77 | 2019-2022 | |
| Eisai INC. | $219.46 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $214.98 | 2022-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $198.95 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $173.99 | 2024-2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $148.06 | 2019-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $108.75 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $104.66 | 2019-2021 | |
| Sage Therapeutics, LLC | $55.26 | 2019-2022 | |
| Shire North American Group INC | $54.47 | 2019 | |
| Alfasigma USA, INC. | $40.43 | 2021-2022 | |
| Biogen, INC. | $39.88 | 2024 | |
| Owp Pharmaceuticals, INC. | $32.26 | 2021-2022 | |
| Indivior INC. | $20.72 | 2020 | |
| Noven Therapeutics, LLC | $19.78 | 2024 | Xelstrym |
| Livanova USA, INC. | $16.20 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.80 | 2025 | Rejoyn |
| Avion Pharmaceuticals | $15.60 | 2023 | Methylphenidate Hydrochloride |
| Arbor Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Friday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.